

CASE REPORT

Idiopathic Interstitial Pneumonia as a Possible Cause of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: **A Case Report**

Hiroshi OIWA,¹ Katsuhiro OOI,² Tetsu OYAMA,³ Eiji SUGYAMA²

¹Department of Rheumatology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan ²Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan ³Department of Rheumatology, Oyama Clinic, Hiroshima, Japan

ABSTRACT

There are conflicting data to date on the causal relationship between idiopathic interstitial pneumonia and antineutrophil cytoplasmic antibody (ANCA): (1) myeloperoxidase-ANCA may play a pathogenetic role in pulmonary fibrosis, or (2) pulmonary fibrosis may induce production of the antibody. In this article, we describe a case of an elderly female patient with microscopic polyangiitis that developed after positive conversion of myeloperoxidase-ANCA during the course of idiopathic interstitial pneumonia. Our experience as well as similar case reports may suggest that idiopathic interstitial pneumonia may induce production of ANCAs and even ANCA-associated vasculitis.

Keywords: Antineutrophil cytoplasmic antibody; idiopathic interstitial pneumonia; microscopic polyangiitis; vasculitis.

There are conflicting data to date on the causal relationship between idiopathic interstitial pneumonia (IIP) and antineutrophil cytoplasmic antibody (ANCA), since they are often observed simultaneously.¹ If patients with IIP are found to have myeloperoxidase (MPO)-ANCA, two possibilities may be considered: MPO-ANCA may play a role in the development of interstitial lung disease/pulmonary fibrosis, or fibrotic process in IIP may induce production of the antibody.

In 2011, Guilpain et al.² showed that seruminduced fibroblast proliferation in vitro was highly increased in microscopic polyangiitis with pulmonary fibrosis compared to that without it, probably through oxidative stress, suggesting the potential of MPO-ANCA to trigger the fibrotic process. However, it remains unknown whether such findings are reproduced in vivo. In this article, we describe the case of a patient with

microscopic polyangiitis that developed after positive conversion of MPO-ANCA during the course of IIP.

CASE REPORT

A 72-year-old female patient was admitted for rapidly progressive glomerulonephritis. Three years previously, she was first suggested to have interstitial pneumonia on health checkup. However, she did not visit the office because she was asymptomatic. One year later, the patient visited the hospital for exertional dyspnea. She also had noticed Raynaud's phenomenon and sicca syndrome for several years. Chest X-ray showed permeability loss of the lower lung fields (Figure 1). High-resolution computed tomography of the lung showed ground-glass opacities with traction bronchiectasis in the peripheral lungs,

Received: June 14, 2017 Accepted: July 17, 2017 Published online: January 17, 2018

Tel: +81-82-221-2291 e-mail: hiroshioiwa@aol.com

©2018 Turkish League Against Rheumatism. All rights reserved.

Correspondence: Hiroshi Oiwa, MD. Department of Rheumatology, Hiroshima City Hiroshima Citizens Hospital, 730-8518 Hiroshima, Japan.



Figure 1. Clinical course of repeated chest X-ray and myeloperoxidase-antineutrophil cytoplasmic antibody. CXR: Chest X-ray; Dx: Diagnosis; IPF: Idiopathic pulmonary fibrosis; RA: Rheumatoid arthritis; DOA: Date of Admission; AAV: Antineutrophil cytoplasmic antibody-associated vasculitis; MPO-ANCA: Myeloperoxidase-antineutrophil cytoplasmic antibody; NA: Not available.

without honeycombing, which was compatible with nonspecific interstitial pneumonia (Figure 2); at that time, laboratory test showed negative result of MPO-ANCA (<1.0 U/mL; normal <3.5 U/mL) (Figure 1). The test for anti-nuclear antibody was positive at 80 folds for homogeneous and speckled pattern (normal range <40 folds); however, the results for anti-topoisomerase, anti-centromere, anti-ribonucleoprotein. anti-ribonucleic acid polymerase III, and anti-Sjögren syndrome antigen A/Ro and anti-Sjögren syndrome antigen B/La antibodies were all negative. Accordingly, the diagnosis of interstitial pneumonia associated with rheumatic disorders was not considered likely. The results of bronchoalveolar fluid



Figure 2. High-resolution computed tomography showed peripheral ground-grass opacities with traction bronchiectasis without honeycombing.

analysis, including cellular profiles, cytology, and culture for bacteria and mycobacterium, were not remarkable. Transbronchial biopsy showed no pathogenic findings. Therefore, patient was considered to have IIP. She was followed-up without therapy. Ten months before admission, she developed polyarthralgia and was suspected to have rheumatoid arthritis following a positive result for rheumatoid factor; at that time, testing for MPO-ANCA showed positive conversion, at 9.0 U/mL. The dipstick test, however, showed negative result for uric blood and protein. Therapy with tacrolimus and celecoxib alleviated her symptoms. Her medical history included cholecystectomy and lumbar compression fracture, and her medication regime comprised tacrolimus, celecoxib, famotidine, and sulfamethoxazole/trimethoprim. She denied a history of fever, sensory disturbance, or rash. On physical examination, body temperature was 36.3°C, blood pressure was 154/94 mmHg, and pulse rate was 95/minute. Respiration rate was 12/minute on room air. There were fine crackles on the lung bases and edema of the legs. No abnormal findings were observed on the heart, the abdomen, the skin or the neuromuscular system. Laboratory test results were as follows: white blood cell, $11130/\mu$ L (neutrophils 75.5%); C-reactive protein, 6.13 mg/dL; urea nitrogen, 42.2 mg/dL; creatinine, 4.23 mg/dL; urine protein. (2+): spot urine protein/creatinine ratio. 2.7; and 24-hour urinary protein excretion, 2.0 urine sediment showed urinary erythrocytes of >300/high-power field, red blood cell cast

	Sex	Age (IPF)	Age (MPA)	Smoking	Time (mo) from IPF to seroconversion	Time (mo) from IIP to onset of MPA	DAH	RV	MM	Skin	Fever	FUP from onset of MPA (mo)	Outcome
Watanabe et al. ⁴	ц	63	64	None	9	9	(-)	(+)	(-)	(-)	(+)	31	Alive
Ando et al. ⁵	Σ	70	NA	Ex	53	NA		(+	NA	NA	(+	NA	Dead
Ando et al. ⁵	Σ	70	NA	Ex	23	NA	(_)	(+)	NA	NA	(+)	NA	Dead
Kagiyama et al. ⁶	Σ	NA	75	NA	NA	72.7	(+)	(+)	(-)	(-)	(+)	0.72	Dead
Kagiyama et al. ⁶	Σ	NA	76	NA	NA	99	(+)	(+)	-	-	(+)	0.96	Dead
Kagiyama et al. ⁶	Σ	NA	76	NA	NA	61.4	(+)	(+)	-	-	(+)	12.5	Dead
Kagiyama et al. ⁶	ц	NA	73	NA	NA	66	(-)	(-)	(+	-	(+)	22.4	Dead
Kagiyama et al. ⁶	ц	NA	60	NA	NA	5	(-)	(+)	-	-	(+)	75.7	Alive
Kagiyama et al. ⁶	Σ	NA	62	NA	NA	64	(-)	(+)	-	-	(+)	1	Alive
Oiwa 2017	ц	70	72	None	29	39	(-)	(+)	(-)	(-)	(-)	19	Alive

of 5-9/high-power field, and granular cast of 1-4/high-power field. The level of MPO-ANCA was highly elevated at 71.2 U/mL. X-ray of the hands did not show significant findings of erosion or joint space narrowing. A retrospective review of chest radiographs revealed slow progression of the pulmonary fibrosis (Figure 1). Computed tomography of the lung also revealed progression of pulmonary fibrosis. Renal biopsy showed necrotizing crescentic glomerulonephritis, leading to the diagnosis of microscopic polyangiitis (MPA). Methylprednisolone pulse therapy, followed by high-dose prednisolone, and intravenous cyclophosphamide improved renal function. Four months after therapy, the levels of urea nitrogen and creatinine were 29.8 mg/dL and 1.55 mg/dL, respectively. A spot urine protein/creatinine ratio was 2.4, while urinary sediment was inactive.

DISCUSSION

Our case was diagnosed to have IIP for the following reasons: (1) her conditions did not suggest known causes of interstitial lung disease such as drug or inhalational exposure or collagen vascular diseases,³ and (2) transbronchial biopsy and bronchoalveolar fluid analysis did not show pathogenic findings for hypersensitivity pneumonia, sarcoidosis or eosinophilic pneumonia. Along with progression of IIP, the test for MPO-ANCA was converted to be positive, and subsequently ANCA-associated renal vasculitis, namely MPA, developed.

To our knowledge, 10 cases with MPA associated with positive conversion of MPO-ANCA following the diagnosis of IIP have been reported in detail (Table 1).⁴⁻⁶ Three of the 10 had diffuse alveolar hemorrhage, nine had renal vasculitis, and six died within a median follow-up period of 15.8 months. Accordingly, the MPA cases developing after the seroconversion following IIP diagnosis may tend to present with pulmonary-renal syndrome, and had a worse outcome.

Kagiyama et al.⁶ vigorously investigated positive conversion of MPO-ANCA in a large cohort of patients with interstitial pulmonary fibrosis and described that the incidence of seroconversion of MPO and proteinase 3 were 13.10 and 12.23 cases per 1,000 person-years, respectively. Of their 468 interstitial pulmonary fibrosis patients without ANCA, six (1.3%) subsequently had MPO-ANCA and MPA over a median follow-up period of 4.02 years.

An analysis of bronchoalveolar lavage fluid showed that the pulmonary fibrosis was associated with higher neutrophil percentages and higher levels of neutrophil-derived enzymes, including MPO, compared with those for healthy controls and patients with scleroderma lung disease.⁷ The neutrophil also has a function to promote pulmonary fibrosis.^{8,9} Sustained activation of neutrophils in IIP may trigger an autoimmunity against MPO and proteinase 3, as seen in several infectious diseases in which ANCAs have been detected.¹⁰

In conclusion, a significant number of MPA cases developing after seroconversion of MPO-ANCA following the diagnosis of IIP has been reported. These observations as well as Kagiyama's work suggest that interstitial pulmonary fibrosis may be a cause, rather than a result, of the production of ANCA, and may even be a cause of MPA.

Declaration of conflicting interests

The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

Funding

The authors received no financial support for the research and/or authorship of this article.

REFERENCES

1. Hervier B, Pagnoux C, Agard C, Haroche J, Amoura Z, Guillevin L, et al. Pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study

of 12 cases and review of the literature. Ann Rheum Dis 2009;68:404-7.

- Guilpain P, Chéreau C, Goulvestre C, Servettaz A, Montani D, Tamas N, et al. The oxidation induced by antimyeloperoxidase antibodies triggers fibrosis in microscopic polyangiitis. Eur Respir J 2011;37:1503-13.
- 3. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733-48.
- Watanabe T, Matsushita H, Uji M, Suzumura T, Nishida K, Hirata K. A case of interstitial pneumonia preceding microscopic polyangiitis. Nihon Kokyuki Gakkai Zasshi 2007;45:615-20.
- Ando M, Miyazaki E, Ishii T, Mukai Y, Yamasue M, Fujisaki H, et al. Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. Respir Med 2013;107:608-15.
- Kagiyama N, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y. Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis. BMJ Open Respir Res 2015;2:e000058.
- 7. Cailes JB, O'Connor C, Pantelidis P, Southcott AM, Fitzgerald MX, Black CM, et al. Neutrophil activation in fibrosing alveolitis: a comparison of lone cryptogenic fibrosing alveolitis and systemic sclerosis. Eur Respir J 1996;9:992-9.
- Gregory AD, Kliment CR, Metz HE, Kim KH, Kargl J, Agostini BA, et al. Neutrophil elastase promotes myofibroblast differentiation in lung fibrosis. J Leukoc Biol 2015;98:143-52.
- Chrysanthopoulou A, Mitroulis I, Apostolidou E, Arelaki S, Mikroulis D, Konstantinidis T, et al. Neutrophil extracellular traps promote differentiation and function of fibroblasts. J Pathol 2014;233:294-307.
- 10. Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006;368:404-18.